MTOR and prostate carcinoma: As expected for PI3K pathway inhibition, global gene expression analysis demonstrated that BAY1082439 treatment led to downregulation of mTOR signaling and cell proliferation-related pathways as well as Ki67 expressions in all 4 prostate cancer cell lines (Fig. 1A; Supplementary Fig. 2A; Supplementary Data 1).